Neogen Corp NEOG
We take great care to ensure that the data presented and summarized in this overview for NEOGEN CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NEOG
View all-
Black Rock Inc. New York, NY25MShares$377 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA19.7MShares$297 Million0.01% of portfolio
-
William Blair Investment Management, LLC Chicago, IL13.3MShares$200 Million0.57% of portfolio
-
Select Equity Group, L.P. New York, NY13.2MShares$200 Million0.89% of portfolio
-
Baillie Gifford & CO11.2MShares$169 Million0.14% of portfolio
-
Conestoga Capital Advisors, LLC8.71MShares$131 Million2.03% of portfolio
-
State Street Corp Boston, MA7.93MShares$120 Million0.01% of portfolio
-
Mackenzie Financial Corp Toronto Ontario, A67.4MShares$112 Million0.19% of portfolio
-
Bamco Inc New York, NY7.3MShares$110 Million0.33% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT7.11MShares$107 Million0.76% of portfolio
Latest Institutional Activity in NEOG
Top Purchases
Top Sells
About NEOG
Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed producers and processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, and veterinary vaccines. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.
Insider Transactions at NEOG
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Nov 01
2024
|
Thierry Bernard Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,620
+50.0%
|
$78,680
$14.44 P/Share
|
Oct 28
2024
|
Catherine E Woteki Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,776
+19.2%
|
$23,088
$13.81 P/Share
|
Oct 28
2024
|
Rafael A Rodriguez Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,776
+19.2%
|
$23,088
$13.81 P/Share
|
Oct 28
2024
|
James P Tobin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,776
+6.07%
|
$23,088
$13.81 P/Share
|
Oct 28
2024
|
Aashima Gupta Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,776
+23.09%
|
$23,088
$13.81 P/Share
|
Oct 28
2024
|
Ronald D Green Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,776
+12.2%
|
$23,088
$13.81 P/Share
|
Oct 28
2024
|
Jeffrey D Capello Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,776
+23.09%
|
$23,088
$13.81 P/Share
|
Oct 28
2024
|
William T Boehm Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,776
+5.38%
|
$23,088
$13.81 P/Share
|
Oct 28
2024
|
James C Borel Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,776
+6.52%
|
$23,088
$13.81 P/Share
|
Oct 28
2024
|
Amy M Rocklin Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,758
-10.39%
|
$35,854
$13.81 P/Share
|
Oct 28
2024
|
Amy M Rocklin Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,475
+26.3%
|
$123,175
$13.81 P/Share
|
Oct 28
2024
|
David H. Naemura Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,450
-14.16%
|
$83,850
$13.81 P/Share
|
Oct 28
2024
|
David H. Naemura Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,504
+25.4%
|
$201,552
$13.81 P/Share
|
Oct 28
2024
|
Douglas Edward Jones Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,512
-5.96%
|
$58,656
$13.81 P/Share
|
Oct 28
2024
|
Douglas Edward Jones Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,504
+17.0%
|
$201,552
$13.81 P/Share
|
Oct 28
2024
|
John Edward Adent CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,280
-4.38%
|
$146,640
$13.81 P/Share
|
Oct 28
2024
|
John Edward Adent CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
38,760
+13.09%
|
$503,880
$13.81 P/Share
|
Oct 24
2024
|
Catherine E Woteki Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,075
+25.88%
|
$78,975
$13.58 P/Share
|
Oct 24
2024
|
Rafael A Rodriguez Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,075
+25.88%
|
$78,975
$13.58 P/Share
|
Oct 24
2024
|
James P Tobin Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,075
+13.97%
|
$78,975
$13.58 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 284K shares |
---|---|
Exercise of conversion of derivative security | 186K shares |
Open market or private purchase | 70.5K shares |
Discretionary transaction | 17.5K shares |
Payment of exercise price or tax liability | 54.5K shares |
---|